Loading, Please Wait...
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, will showcase innovative RNA sequencing applications using microfluidics technology at the American Society of Human Genetics (ASHG) annual meeting in Houston, Texas, from October 15 to 19.
"As the demand for RNA NGS sequencing continues to rise, many genomics laboratories have found it challenging to affordably scale NGS library preparation," said Chris Linthwaite, President and CEO of Fluidigm. "This year at ASHG, we are excited to showcase a breakthrough automated RNA sequencing library preparation workflow that enables laboratories to efficiently produce 48 libraries at a time while substantially reducing their cost per sample. By automating the library prep workflow, shortening hands-on time and decreasing consumables waste, we can bring operational savings to mid-to-high-throughput laboratories using microfluidics technology that could amount to hundreds of thousands of dollars.”
Featured RNA Sequencing and Genomic Applications
Exhibitor Workshops Utilizing Fluidigm Microfluidics Technology
More information on the Fluidigm products and presentations can be found at Fluidigm Booth 1107 or at fluidigm.com/ashg2019.
Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, Advanta, C1, CyTOF, Juno and Open App are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Forward-Looking Statement for Fluidigm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the anticipated benefits to customers of, and applications for, Fluidigm products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2018, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Senior Director, Marketing
650 737 4190
Vice President, Investor Relations
650 416 7423